Auxogyn recently announced a deal awarding Merck rights to market in Europe and Canada a novel test designed to improve the efficiency and outcomes of in vitro fertilization. The test, known as Eeva, allowed embryologists who used it to identify embryos that were nonviable 86% of the time, compared with 58% of the time without the test, the company said. And company CEO and President Lissa Goldenstein says Auxogyn will continue to advance the technology, which is under regulatory consideration in the U.S.

Related Summaries